Kiora Pharmaceuticals, Inc. - Common Stock KPRX 深 滬
等待開盤 04-01 09:30:00 美东时间
1.93
+0.040
+2.12%
華盛通- 最 高1.94
- 今 開1.88
- 成交量 3.36万股
- 最 低 1.85
- 昨 收 1.89
- 總市值 709.83万
- 52周最高 4.18
- 市盈率 靜 --
- 換手率 0.91%
- 52周最低 1.7645
- 委 比 61.68%
- 總股本 367.79万
- 歷史最高 189000.00
- 量 比 0.96
- 振 幅 4.76%
- 歷史最低 1.7645
- 每 手 1
- 風險率 0.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Kiora Pharmaceuticals Q4 EPS $(1.60) Misses $(0.67) Estimate
Kiora Pharmaceuticals (NASDAQ:KPRX) reported quarterly losses of $(1.60) per share which missed the analyst consensus estimate of $(0.67) by 138.81 percent. This is a 61.62 percent decrease over losses of $(0.99) per
03-26 06:17
Kiora Pharmaceuticals GAAP EPS of -$2.64
Kiora Pharmaceuticals press release (KPRX): FY GAAP EPS of -$2.64. Ended 2025 with $17.1 million in cash, cash equivalents, and short-term investments, plus $3.5 million in receivables consisting of $...
03-25 19:12
Kiora Pharmaceuticals posts 2025 net loss as expenses rise
Kiora Pharmaceuticals posts 2025 net loss as expenses rise Overview US retinal disease biotech posted 2025 net loss, reversing prior yr profit R&D and G&A expenses rose in 2025, mainly due to clinical trial activity and personnel Company ended 2025 with $17.1 mln in cash, expects runway into late 20
03-25 19:10
Kiora Pharmaceuticals FY2025 net loss widens 401% to $11 million; revenue drops to no revenue
Kiora Pharmaceuticals FY2025 net loss widens 401% to $11 million; revenue drops to no revenue FY2025 net loss swung to $10.8 million from net income of $3.6 million, on no collaboration revenue versus $16.0 million a year earlier. FY2025 loss per share widened to $2.60 from $0.93 per share. Q4 FY202
03-25 19:03
Kiora Pharmaceuticals to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Kiora Pharmaceuticals to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference Kiora Pharmaceuticals, Inc. will present at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 3:20 p.m. ET. A live webcast will be accessible via Kiora’s investor rela
02-19 21:32
Kiora Pharmaceuticals Secures New US Patent to Expand Delivery Options for Eye Drug KIO-104
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) today announced that the U.S. Patent and Trademark Office issued a new patent (US-12,472,263) on additional and novel formulations of the KIO-100 family of compounds, This patent
2025-12-01 20:11
Kiora Pharmaceuticals Granted U.S. Patent for Novel KIO-104 Anti-Inflammatory Formulations
Kiora Pharmaceuticals Inc. has announced the issuance of a new U.S. patent (US-12,472,263) covering additional and novel formulations for its KIO-100 family of anti-inflammatory compounds. The patent ...
2025-12-01 19:46
Kiora Pharmaceuticals Reports Improved Financial Performance
Kiora Pharmaceuticals, Inc. ( ($KPRX) ) has released its Q3 earnings. Here is a...
2025-11-11 12:30
Earnings Scheduled For November 7, 2025
Companies Reporting Before The Bell • Kiora Pharmaceuticals (NASDAQ:KPRX) is pr...
2025-11-07 19:11
Kiora Pharmaceuticals posts third quarter results and reports ongoing Phase 2 trials for retinal diseases
Kiora Pharmaceuticals Inc. reported third quarter 2025 results, ending the period with $19.4 million in cash, cash equivalents, and short-term investments. The company recorded $1.2 million in collabo...
2025-11-07 19:01
